

GC Pharma receives approval for seasonal influenza vaccine

01 October 2018 | News

With this approval, providers are now able to use the GCFLU Quadrivalent to vaccinate all eligible persons from 6 months and older.



GC Pharma (formerly known as Green Cross) has announced that it has received approval from the South Korean Ministry of Food and Drug Safety (MFDS) expanding the indication for GCFLU Quadrivalent (Seasonal Influenza Vaccine) to include use in persons 6 months and older. Prior to this, the vaccine was approved for use in persons 3 years of age and older.

"The flu is a serious diseases with a significant impact on public health," said Byung-Wha Kim GC Pharma Executive Vice President. "The expanded indication builds upon GC Pharma's legacy as the first local manufacturer to bring quadrivalent flu vaccines to the South Korean marketplace."

With this approval, providers are now able to use the GCFLU Quadrivalent to vaccinate all eligible persons from 6 months and older.

This expanded indication for the vaccine was based on Phase III clinical studies conducted in children 6 months through 35 months of age.

GCFLU Quadrivalent was first approved in 2015 in South Korea for the prevention of influenza disease. It has also received prequalification status from the World Health Organization (WHO).